Science
In Early Trial, Precision T-Cell Drug Invika Halted Cancer Progression in 16 of 27 Patients Treated at Optimal Doses
An experimental drug called invikafusp alfa, known as invika, held back cancer progression in 16 of 27 patients treated at its optimal doses in an early human trial, the National Institutes of Health reported.
By Darrell Wallen · Oct 28, 2026 · ≈22 min listen · Read →

